

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



Product Data Sheet

18β-Glycyrrhetinic acid

 Cat. No.:
 HY-N0180

 CAS No.:
 471-53-4

 Molecular Formula:
 C₃₀H₄₆O₄

 Molecular Weight:
 470.68

 Target:
 Endogenous Metabolite

 Pathway:
 Metabolic Enzyme/Protease

Storage: Powder -20°C

4°C 2 years -80°C 1 year

3 years

In solvent -80°C 1 year

-20°C 6 months

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (265.57 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1246 mL	10.6229 mL	21.2459 mL
	5 mM	0.4249 mL	2.1246 mL	4.2492 mL
	10 mM	0.2125 mL	1.0623 mL	2.1246 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 50% PEG300 >> 50% saline Solubility: 25 mg/mL (53.11 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (4.61 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.17 mg/mL (4.61 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

 18β -Glycyrrhetinic acid is the major bioactive component of Glycyrrhiza uralensis and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties.

In Vitro

 18β -Glycyrrhetinic acid is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties. MTS assay demonstrates that 24 h treatment of 18β -Glycyrrhetinic acid suppresses cell proliferation in both cell lines in a dose-dependent manner. 18β -Glycyrrhetinic acid at 160μ M significantly decreases the percentage of viable cells to around $40.5\pm10.5\%$ in A549 and $38.3\pm4.6\%$ in NCI-H460 (p<0.01 respectively).

When the cells are treated with 320 μ M 18 β -Glycyrrhetinic acid, a greater inhibitory effects on cell proliferation is shown, as the percentage of viable cells is below 30% compare with untreated controls (p<0.001). Treatment with 18 β -Glycyrrhetinic acid at 160 μ M and 320 μ M decreases the levels of full-length PARP and increases the levels of cleaved-PARP^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rats in 18β -Glycyrrhetinic acid+Triptolide (TP) group which receive low-dose 18β -Glycyrrhetinic acid (50 mg/kg) have significant reductions in the three serum parameters when compare with TP rats. Rats in 18β -Glycyrrhetinic acid+TP group which receive the high-dose 18β -Glycyrrhetinic acid (100 mg/kg) have slightly lowered the levels of three liver enzymes, the reductions do not reach statistical significance compare with TP group. Contrastingly, preadministration of low-dose 18β -Glycyrrhetinic acid protects animals from TP-induced hepatic lesions. On the contrary, low-dose 18β -Glycyrrhetinic acid (50 mg/kg) markedly suppresses the release of the four cytokines above [3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay [2]

Primary microglia cultures are used in this study. For treatment assay, microglia are incubated with complete DMEM and stimulated with or without 100 ng/mL IFN- γ in the presence or absence of 18 β -Glycyrrhetinic acid (25 μ M and 50 μ M) at 37°C in a humidified incubator with 5% CO₂. For cell migration assay, the isolated primary microglia that seeded in complete DMEM medium are stimulated with or without IFN- γ (100 ng/mL), and treated with different doses of 18 β -Glycyrrhetinic acid , 24 h later, the microglia culture supernatants are collected and added to the lower chambers of Transwell inserts^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration [3]

Healthy Wistar rats (male, 200 ± 20 g) are used and divided into five groups with 10 individuals for each group randomly. Animals in normal control (NC) group receive distilled water for 6 days and 0.5% CMC-Na for the last 3 days. Rats in Triptolide model group (TP), 18β -Glycyrrhetinic acid low-dose group (GAL+TP), and 18β -Glycyrrhetinic acid high-dose group (GAH+TP) receive distilled water, 18β -Glycyrrhetinic acid (50 mg/kg, p.o., dissolved in distilled water), or 18β -Glycyrrhetinic acid (100 mg/kg, p.o., dissolved in distilled water) for consecutive 6 days, respectively, and liver injury is induced by TP (2.4 mg/kg, p.o., suspended in 0.5% CMC-Na) for the last 3 days. Animals in the above three groups receive TP 6 hours after distilled water or 18β -Glycyrrhetinic acid treatment on the last 3 days^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Adv Sci (Weinh). 2024 Jan 6:e2305260.
- Chemosphere. 2023 Feb 24;138249.
- Cell Prolif. 2023 May 4;e13494.
- Environ Toxicol. 2022 Aug 3.
- World J Gastroenterol. 2023 Jun 21; 29(23): 3622-3644.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

[1]. Huang RY, et al. 18β-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS One. 2014 Apr 2;9(4):e93690.

[2]. Zhou J, et al. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Sci Rep. 2015 Sep 2;5:13713.

B]. Yang G, et al. Protective Effe	ect of 18β-Glycyrrhetinic Acid a	gainst Triptolide-Induced Hepat	otoxicity in Rats. Evid Based Complement Alte	rnat Med. 2017;2017:3470320.
	Caution: Product has not	been fully validated for med	ical applications. For research use only.	
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.com	
	Address: 1 D	eer Park Dr, Suite Q, Monmou	th Junction, NJ 08852, USA	

Page 3 of 3 www.MedChemExpress.com